This excerpt taken from the TPTX 8-K filed Jun 8, 2006.
During the next 12 months, TorreyPines and Axonyx anticipate several key milestones related to their product candidates. Among these include the following:
TorreyPines lead compound, tezampanel, is expected to enter a Phase IIb clinical trial for the treatment of migraine
TorreyPines expects to file an Investigational New Drug (IND) application and then begin a Phase I trial for NGX426, the oral prodrug of tezampanel and the companys follow-on compound for migraine and chronic pain
Axonyx will complete its ongoing Phase I trials with Posiphen for the treatment of AD progression
Data will become available from TorreyPines Phase I single dose study evaluating NGX267, the companys lead muscarinic agonist, in healthy elderly volunteers a population reflecting the age of the primary AD population
TorreyPines plans to initiate a multiple dose Phase I safety study with NGX267
Axonyx to begin a Phase I clinical trial with BNC, its highly selective butyrylcholinesterase inhibitor for the treatment of severe AD
Skip the spreadsheet. Track your investments automatically.